1. Home
  2. ARTL vs ENSC Comparison

ARTL vs ENSC Comparison

Compare ARTL & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARTL
  • ENSC
  • Stock Information
  • Founded
  • ARTL 2011
  • ENSC 2003
  • Country
  • ARTL United States
  • ENSC United States
  • Employees
  • ARTL N/A
  • ENSC N/A
  • Industry
  • ARTL Biotechnology: Pharmaceutical Preparations
  • ENSC Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARTL Health Care
  • ENSC Health Care
  • Exchange
  • ARTL Nasdaq
  • ENSC Nasdaq
  • Market Cap
  • ARTL 3.1M
  • ENSC 3.4M
  • IPO Year
  • ARTL N/A
  • ENSC N/A
  • Fundamental
  • Price
  • ARTL $1.05
  • ENSC $2.22
  • Analyst Decision
  • ARTL Strong Buy
  • ENSC
  • Analyst Count
  • ARTL 2
  • ENSC 0
  • Target Price
  • ARTL $5.50
  • ENSC N/A
  • AVG Volume (30 Days)
  • ARTL 47.0K
  • ENSC 302.7K
  • Earning Date
  • ARTL 05-13-2025
  • ENSC 05-13-2025
  • Dividend Yield
  • ARTL N/A
  • ENSC N/A
  • EPS Growth
  • ARTL N/A
  • ENSC N/A
  • EPS
  • ARTL N/A
  • ENSC N/A
  • Revenue
  • ARTL N/A
  • ENSC $6,224,081.00
  • Revenue This Year
  • ARTL N/A
  • ENSC N/A
  • Revenue Next Year
  • ARTL N/A
  • ENSC $1,381.48
  • P/E Ratio
  • ARTL N/A
  • ENSC N/A
  • Revenue Growth
  • ARTL N/A
  • ENSC 256.35
  • 52 Week Low
  • ARTL $0.82
  • ENSC $1.62
  • 52 Week High
  • ARTL $1.55
  • ENSC $14.67
  • Technical
  • Relative Strength Index (RSI)
  • ARTL 58.54
  • ENSC 45.34
  • Support Level
  • ARTL $0.90
  • ENSC $2.13
  • Resistance Level
  • ARTL $1.02
  • ENSC $2.40
  • Average True Range (ATR)
  • ARTL 0.07
  • ENSC 0.22
  • MACD
  • ARTL 0.01
  • ENSC 0.02
  • Stochastic Oscillator
  • ARTL 62.18
  • ENSC 35.94

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: